[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019008359A - Cadena j modificada. - Google Patents

Cadena j modificada.

Info

Publication number
MX2019008359A
MX2019008359A MX2019008359A MX2019008359A MX2019008359A MX 2019008359 A MX2019008359 A MX 2019008359A MX 2019008359 A MX2019008359 A MX 2019008359A MX 2019008359 A MX2019008359 A MX 2019008359A MX 2019008359 A MX2019008359 A MX 2019008359A
Authority
MX
Mexico
Prior art keywords
chain
modified
antibodies
same
present
Prior art date
Application number
MX2019008359A
Other languages
English (en)
Inventor
Keyt Bruce
George Presta Leonard
Zhang Fen
BALIGA Ramesh
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of MX2019008359A publication Critical patent/MX2019008359A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

La presente invención implica polipéptidos de cadena J recombinantes modificados, moléculas de unión, tal como anticuerpos que los comprenden, y sus usos.
MX2019008359A 2014-04-03 2015-04-02 Cadena j modificada. MX2019008359A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461974738P 2014-04-03 2014-04-03
PCT/US2015/024149 WO2015153912A1 (en) 2014-04-03 2015-04-02 Modified j-chain

Publications (1)

Publication Number Publication Date
MX2019008359A true MX2019008359A (es) 2019-09-16

Family

ID=52998235

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016012880A MX366588B (es) 2014-04-03 2015-04-02 Cadena j modificada.
MX2019008359A MX2019008359A (es) 2014-04-03 2015-04-02 Cadena j modificada.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016012880A MX366588B (es) 2014-04-03 2015-04-02 Cadena j modificada.

Country Status (21)

Country Link
US (5) US10400038B2 (es)
EP (3) EP4011910A1 (es)
JP (2) JP6744822B2 (es)
KR (3) KR20230155600A (es)
CN (2) CN106459213B (es)
AU (3) AU2015240595B2 (es)
BR (1) BR112016022841B1 (es)
CA (1) CA2944647A1 (es)
DK (2) DK3126383T3 (es)
ES (2) ES2887299T3 (es)
HU (2) HUE055693T2 (es)
IL (3) IL278350B (es)
MX (2) MX366588B (es)
NZ (1) NZ725568A (es)
PL (2) PL3126383T3 (es)
PT (2) PT3126383T (es)
RU (2) RU2021134101A (es)
SG (2) SG10201909716RA (es)
SI (2) SI3126383T1 (es)
WO (1) WO2015153912A1 (es)
ZA (1) ZA201606906B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014332458B2 (en) 2013-09-05 2020-03-12 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
CA3183645A1 (en) 2013-10-25 2015-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
IL278350B (en) * 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
SG11201705116SA (en) 2015-01-20 2017-08-30 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HUE054642T2 (hu) * 2015-03-04 2021-09-28 Igm Biosciences Inc CD20 kötõ molekulák és ezek felhasználása
KR102558839B1 (ko) 2015-03-25 2023-07-25 아이쥐엠 바이오사이언스 인코포레이티드 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
CN108463472A (zh) * 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j-链的结合分子
EP3355913B1 (en) * 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EA201891021A1 (ru) * 2015-12-17 2018-11-30 Псайоксус Терапьютикс Лимитед Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
PT3455257T (pt) 2016-05-09 2021-12-06 Igm Biosciences Inc Anticorpos anti-pd-l1
JP2019532621A (ja) 2016-08-29 2019-11-14 サイオクサス セラピューティクス リミテッド 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018148445A1 (en) 2017-02-08 2018-08-16 Adimab, Llc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics Inc proteínas que se ligam a her2, nkg2d e cd16
WO2018187702A2 (en) 2017-04-07 2018-10-11 Igm Biosciences A/S Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
AU2019227984A1 (en) * 2018-03-01 2020-09-10 Igm Biosciences, Inc. IgM Fc and J-chain mutations that affect IgM serum half-life
US20220162312A1 (en) * 2019-01-28 2022-05-26 WuXi Biologics Ireland Limited Novel bispecific cd3/cd20 polypeptide complexes
US20230203119A1 (en) 2019-08-15 2023-06-29 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
AU2020351205A1 (en) * 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
AU2020353182A1 (en) * 2019-09-27 2022-04-14 Beijing Starmab Biomed Technology Ltd Monospecific and multi-specific antibodies
CN115485299A (zh) 2020-04-22 2022-12-16 Igm生物科学股份有限公司 Pd-1激动剂多聚结合分子
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection
AU2023249803A1 (en) 2022-04-07 2024-11-07 Repertoire Immune Medicines, Inc. T cell receptor multimers and uses thereof

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8719963D0 (en) 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US5831034A (en) 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE69030172T2 (de) 1990-01-26 1997-06-19 Immunomedics Inc Impfstoffe gegen Krebs und Infektionskrankheiten
ATE314479T1 (de) 1992-05-18 2006-01-15 Genentech Inc Aktivierung von rezeptoren fähig zur oligomerisierung durch verwendung von fusionierten rezeptor liganden
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
IL111196A0 (en) 1994-10-07 1994-12-29 Yeda Res & Dev Peptides and pharmaceutical compositions comprising them
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU2308595A (en) 1995-04-19 1996-11-07 Polymun Scientific Immunobiologische Forschung Gmbh Monoclonal antibodies against hiv-1 and vaccines made thereo f
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
AU740918B2 (en) * 1997-01-10 2001-11-15 Plantibodies Corporation Novel epithelial tissue targeting agent
US20040009166A1 (en) 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
WO1999054484A1 (en) 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
SK288176B6 (sk) 1999-01-07 2014-04-02 Zymogenetics, Inc. Farmaceutický prostriedok obsahujúci fúzny proteín, izolovaná molekula polynukleotidu, expresný vektor, kultivovaná bunka, spôsob prípravy polypeptidu a izolovaný polypeptid
JP2002544123A (ja) 1999-04-14 2002-12-24 スミスクライン・ビーチャム・コーポレイション エリトロポイエチン受容体抗体
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
WO2000074718A1 (en) 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
AU6781700A (en) 1999-08-17 2001-03-13 Health Research Institute Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
HUP0300369A2 (hu) 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
ES2332872T3 (es) 2000-04-28 2010-02-15 Planet Biotechnology, Inc. Inmunoadhesina para la prevencion de la infeccion por rinovirus.
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
MXPA02011092A (es) 2000-05-10 2004-08-19 David A Sirbasku Composiciones y metodos para demostrar la regulacion del sistema inmune secretor del crecimiento de la celula de cancer que responde a la hormona esteroidea.
WO2002004522A2 (en) 2000-07-10 2002-01-17 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US7972845B2 (en) 2000-09-07 2011-07-05 Case Western Reserve University Human antibodies against Pseudomonas aeruginosa LPS derived from transgenic xenomouse
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR20090010127A (ko) 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
NZ513418A (en) 2001-08-07 2004-04-30 Univ Massey Vaccine comprising proteins from mycobacterium paratuberculosis
CA2464239C (en) 2001-10-23 2016-07-12 Psma Development Company, L.L.C. Psma antibodies and protein multimers
JP4498746B2 (ja) 2002-02-14 2010-07-07 イミューノメディクス、インコーポレイテッド 抗ｃｄ２０抗体およびその融合タンパク質ならびに使用法
CN102174108B (zh) 2002-03-01 2016-06-29 免疫医疗公司 内在化抗-cd74抗体和使用方法
ES2871905T3 (es) 2002-03-01 2021-11-02 Immunomedics Inc Inmunoconjugado que comprende anticuerpos de RS7 humanizados
CA2481207C (en) 2002-04-12 2015-06-30 Medarex, Inc. Methods of treatment using ctla-4 antibodies
EP1519958B1 (en) 2002-06-14 2014-10-15 Immunomedics, Inc. Humanized monoclonal antibody hpam4
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040156826A1 (en) 2002-09-27 2004-08-12 Fernando Dangond Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
ATE469920T1 (de) 2003-05-23 2010-06-15 Crucell Holland Bv Herstellung von rekombinanten igm in den per.c6 zellen
EP1652925B1 (en) 2003-07-15 2010-12-08 Chugai Seiyaku Kabushiki Kaisha IgM PRODUCTION BY TRANSFORMED CELLS AND METHODS FOR QUANTIFYING SAID IgM PRODUCTION
WO2005012493A2 (en) 2003-07-31 2005-02-10 Immunomedics, Inc. Anti-cd19 antibodies
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
PL1673398T3 (pl) 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecyficzne deimmunizowane cząsteczki wiążące CD3
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
EP1706425A2 (en) 2003-12-05 2006-10-04 John R. Schreiber Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse®
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
ES2551502T3 (es) 2004-11-05 2015-11-19 Igm Biosciences, Inc. Formación de heridas en la membrana celular inducida por anticuerpos
US7251164B2 (en) 2004-11-10 2007-07-31 Innovative Silicon S.A. Circuitry for and method of improving statistical distribution of integrated circuits
EP1833848A2 (en) 2004-12-09 2007-09-19 Lajolla Institute for Allergy and Immunology Novel tnf receptor regulatory domain
CN103936859A (zh) 2005-03-03 2014-07-23 免疫医疗公司 人源化l243抗体
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8333971B2 (en) 2006-05-15 2012-12-18 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
US20110129412A1 (en) 2005-06-02 2011-06-02 Astrazeneca Ab Antibodies Directed to CD20 and Uses Thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
EP1981532A4 (en) 2005-12-21 2010-06-30 Medimmune Llc EPHA2 MOLECULES AND USES THEREOF
AU2007252295B2 (en) 2006-05-19 2013-07-25 Central Adelaide Local Health Network Incorporated Selective modulation of receptor signalling
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
CN101512008B (zh) 2006-09-08 2015-04-01 艾伯维巴哈马有限公司 白介素-13结合蛋白
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
EP2078040B1 (en) 2006-11-02 2017-06-28 Daniel J. Capon Methods of producing hybrid polypeptides with moving parts
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
EP2087111A2 (en) 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
WO2008135963A2 (en) 2007-05-02 2008-11-13 Hemogem Inc. Fibrinogen for treatment of bleeding in trauma and platelet disorders
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
AU2007358569B2 (en) 2007-09-07 2014-09-04 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
WO2009106073A2 (en) 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
AU2009268352A1 (en) 2008-07-11 2010-01-14 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate kappa light chain sequences
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
JP5851419B2 (ja) 2009-12-29 2016-02-03 エマージェント プロダクト デベロップメント シアトル， エルエルシー ヘテロダイマー結合タンパク質およびその使用
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
SG182823A1 (en) 2010-02-11 2012-09-27 Alexion Pharma Inc Therapeutic methods using an ti-cd200 antibodies
AU2011318567B2 (en) 2010-10-19 2017-02-09 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
CN104185641A (zh) 2011-10-24 2014-12-03 艾伯维公司 针对tnf和il-17的双特异性免疫结合剂
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US20150010544A1 (en) 2011-12-16 2015-01-08 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9409976B2 (en) 2012-02-08 2016-08-09 Igm Biosciences, Inc. CDIM binding proteins and uses thereof
JP6238958B2 (ja) 2012-04-05 2017-11-29 ゴットフリート・ヒムラー 分泌型免疫グロブリン複合体
IN2014MN02274A (es) * 2012-04-17 2015-08-07 Mayo Foundation
WO2013188870A2 (en) 2012-06-15 2013-12-19 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
CN103570821A (zh) * 2012-07-27 2014-02-12 北京智飞绿竹生物制药有限公司 粘蛋白-1抗原性多肽及其作为肿瘤疫苗的用途
US9540442B2 (en) 2012-08-02 2017-01-10 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10066238B2 (en) 2013-02-11 2018-09-04 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
AU2014332458B2 (en) 2013-09-05 2020-03-12 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
AU2015206002B2 (en) 2014-01-16 2020-06-11 Mario Umberto Francesco MONDELLI Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
IL278350B (en) * 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
SG11201705116SA (en) 2015-01-20 2017-08-30 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HUE054642T2 (hu) 2015-03-04 2021-09-28 Igm Biosciences Inc CD20 kötõ molekulák és ezek felhasználása
KR102558839B1 (ko) 2015-03-25 2023-07-25 아이쥐엠 바이오사이언스 인코포레이티드 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
CN108463472A (zh) 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j-链的结合分子
PT3455257T (pt) 2016-05-09 2021-12-06 Igm Biosciences Inc Anticorpos anti-pd-l1
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERIC MOLECULES ATTACHING CD40 AND USES THEREOF
AU2017299608A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric CD137/4-1BB binding molecules and uses thereof
JP2019528683A (ja) 2016-07-20 2019-10-17 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体ｇｉｔｒ結合分子及びその使用
WO2018017888A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
WO2018187702A2 (en) 2017-04-07 2018-10-11 Igm Biosciences A/S Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
KR20200123782A (ko) 2018-02-26 2020-10-30 아이쥐엠 바이오사이언스 인코포레이티드 암치료를 위해 화학치료제와 병용된 다중결합 항-dr5 결합분자의 용도
AU2019227984A1 (en) 2018-03-01 2020-09-10 Igm Biosciences, Inc. IgM Fc and J-chain mutations that affect IgM serum half-life
US20210380701A1 (en) 2018-10-23 2021-12-09 Igm Biosciences, Inc. MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
WO2020163646A1 (en) 2019-02-08 2020-08-13 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
US20230203119A1 (en) 2019-08-15 2023-06-29 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
CA3147767A1 (en) 2019-08-17 2021-02-25 Igm Biosciences, Inc. Multimeric bispecific anti-cd123 binding molecules and uses thereof
CN114269380A (zh) 2019-08-23 2022-04-01 Igm生物科学股份有限公司 IgM糖变体
AU2020351205A1 (en) 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
WO2021141902A1 (en) 2020-01-06 2021-07-15 Igm Biosciences, Inc. Highly sialylated multimeric binding molecules
CN115485299A (zh) 2020-04-22 2022-12-16 Igm生物科学股份有限公司 Pd-1激动剂多聚结合分子
WO2021231639A1 (en) 2020-05-12 2021-11-18 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer
AU2021315513A1 (en) 2020-07-27 2023-03-02 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
US20240002526A1 (en) 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
US20220267415A1 (en) 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
WO2022178047A1 (en) 2021-02-17 2022-08-25 Igm Biosciences, Inc. Anti-cd123 binding molecules and uses thereof

Also Published As

Publication number Publication date
PL3126383T3 (pl) 2019-08-30
KR20230155600A (ko) 2023-11-10
IL248151A0 (en) 2016-11-30
CN112759650B (zh) 2024-10-01
EP3126383A1 (en) 2017-02-08
US9951134B2 (en) 2018-04-24
NZ725568A (en) 2022-10-28
AU2020201347A1 (en) 2020-03-12
US20170283510A1 (en) 2017-10-05
SI3560954T1 (sl) 2021-11-30
BR112016022841A2 (pt) 2017-10-17
JP2017512815A (ja) 2017-05-25
SG11201608194VA (en) 2016-10-28
EP3126383B8 (en) 2019-02-27
CA2944647A1 (en) 2015-10-08
US10975147B2 (en) 2021-04-13
KR20220044377A (ko) 2022-04-07
US11555075B2 (en) 2023-01-17
RU2016141579A3 (es) 2018-12-26
JP6744822B2 (ja) 2020-08-19
AU2020201347B2 (en) 2022-03-10
RU2761118C2 (ru) 2021-12-06
AU2015240595A1 (en) 2016-11-03
CN106459213A (zh) 2017-02-22
AU2022201585A1 (en) 2022-03-31
US10400038B2 (en) 2019-09-03
PL3560954T3 (pl) 2021-12-13
ZA201606906B (en) 2021-07-28
ES2887299T3 (es) 2021-12-22
ES2717704T3 (es) 2019-06-24
US20230279111A1 (en) 2023-09-07
EP3126383B1 (en) 2018-12-19
HUE055693T2 (hu) 2021-12-28
SG10201909716RA (en) 2019-11-28
EP4011910A1 (en) 2022-06-15
IL292311A (en) 2022-06-01
US20200190190A1 (en) 2020-06-18
JP2020114828A (ja) 2020-07-30
MX366588B (es) 2019-07-15
CN106459213B (zh) 2020-12-01
RU2021134101A (ru) 2022-03-22
SI3126383T1 (sl) 2019-05-31
DK3560954T3 (da) 2021-09-06
HUE042829T2 (hu) 2019-07-29
AU2015240595B2 (en) 2020-02-27
JP7062025B2 (ja) 2022-05-02
US20190002566A1 (en) 2019-01-03
BR112016022841A8 (pt) 2018-06-12
BR112016022841B1 (pt) 2023-09-26
PT3126383T (pt) 2019-03-22
EP3560954B1 (en) 2021-08-04
WO2015153912A1 (en) 2015-10-08
PT3560954T (pt) 2021-09-07
EP3560954A1 (en) 2019-10-30
IL278350B (en) 2022-06-01
MX2016012880A (es) 2017-05-12
DK3126383T3 (en) 2019-04-01
KR102380402B1 (ko) 2022-03-31
RU2016141579A (ru) 2018-05-10
CN112759650A (zh) 2021-05-07
US20170183409A1 (en) 2017-06-29
KR20160142345A (ko) 2016-12-12

Similar Documents

Publication Publication Date Title
NZ725568A (en) Modified j-chain
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12017502180A1 (en) Tau-binding antibodies
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2022008781A (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12017502207A1 (en) Tau-binding antibodies
PH12020550243A1 (en) Anti-tau antibodies and uses thereof
PH12016501763A1 (en) Multispecific antibodies
MX2019007021A (es) Anticuerpos il-11ra.
PH12016501700A1 (en) Combination therapies with anti-cd38 antibodies
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
EP3166959A4 (en) Targeting peptides that bind s. mutans, constructs comprising such peptides and uses thereof
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
MX2018008302A (es) Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
NZ731491A (en) Cd83 binding proteins and uses thereof
HK1252350A1 (zh) Mrka多肽、抗體及其用途